This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA®
Bladder Cancer Detection
CORE-001 Study
EV-302
Immunotherapy in NMIBC
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher® Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
mCRPC with Bone Metastasis
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Urologic Catheters (Includes CAUTI)
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Actionable Clinical Data
Bladder Cancer
LG-IR NMIBC
Adstiladrin®
Kidney Cancer
ZIRCON
Trials in Progress
Trials in Progress
Bladder Cancer
BOND-003 Cohort P
CORE-008
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AUA 2025
PSMA and Beyond 2025 Conference
EAU 2025
SES AUA 2025
Thought Leaders 2025
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Video Lectures
PSMA and Beyond 2025 Conference Videos
The Value of Animal Models in Evaluating PSMA-Targeted RPT and Non-RPT Therapies "Presentation" - Deborah Charych
April 23, 2025
Details
Antibody-Drug Conjugates in Prostate Cancer Treatment "Presentation" - John Lee
April 23, 2025
Details
GRPR Antagonists Beyond PSMA in Prostate Cancer Detection and Treatment "Presentation" - Andrei Iagaru
April 23, 2025
Details
PSMA-Targeted Immunotherapy: CAR T and Bispecific T Cell Engagers "Presentation" - Tanya Dorff
April 22, 2025
Details
Beyond Lutetium PSMA: Exploring Terbium-161 for Treatment-Resistant Prostate Cancer "Presentation" - Michael Hofman
April 22, 2025
Details
Comparing PSMA-617 and PSMA-I&T Radiopharmaceuticals for Prostate Cancer Therapy "Presentation" - Matthias Eiber
April 21, 2025
Details
Are We Optimally Dosing Patients with PSMA Radiopharmaceutical Therapy? "Presentation" - Amir Iravani
April 21, 2025
Details
PSMA RLT: A Private Medical Oncology Delivery Model "Presentation" - Luke Nordquist
April 20, 2025
Details
How Does PSMA RLT Kill Cells? Alpha vs Beta Radiobiology "Presentation" - Ana Ponce Kiess
April 19, 2025
Details
Clinical Experience with Actinium-PSMA Across Multiple Treatment Centers "Presentation" - Alfred Morgenstern
April 18, 2025
Details
Next-Generation PSMA Radioligands "Presentation" - Martin Pomper
April 18, 2025
Details
Lessons from Radiation Oncology: How Can We Improve PSMA RLT? "Presentation" - Daniel Spratt
April 18, 2025
Details
Dry Mouth Prevention and Management for PSMA Radioligand Therapy "Presentation" - Sue Yom
April 18, 2025
Details
PSMA-Targeted Antibodies for Prostate Cancer Radioligand Therapy "Presentation" - Scott Tagawa
April 17, 2025
Details
How are we Getting Paid for Theranostics and Dosimetry? "Presentation" - Denise Merlino
April 17, 2025
Details
Beyond the 23 Gy Threshold: Renal Toxicity, EBRT, and RLT "Presentation" - Ana Ponce Kiess
April 17, 2025
Details
PSMA RLT: Radiation Oncology and Health-System Perspective "Presentation" - Dustin Boothe
April 16, 2025
Details
Reimagining PSMA Radioligand Therapy for Castration-Sensitive Prostate Cancer "Presentation" - Michael Morris
April 16, 2025
Details
Lutetium PSMA Beyond Six Cycles Extended Treatment and Re-Challenge Approaches "Presentation" - Matthias Eiber
April 15, 2025
Details
When Should We Use 18F-FDG PET? "Presentation" - Andrei Iagaru
April 15, 2025
Details
Overview of Clinical Trials of PSMA RPT in 2025 "Presentation" - Jeremie Calais
April 15, 2025
Details
Post-Treatment SPECT Imaging for Personalized Radiopharmaceutical Therapy "Presentation" - Carlos Uribe
April 15, 2025
Details
AI Applications for Simplifying Radiopharmaceutical Dosimetry Workflows "Presentation" - Irène Buvat
April 15, 2025
Details
Sequencing with RLT in mCRPC "Presentation" - Tanya Dorff
April 14, 2025
Details
PSMA RLT for Oligometastatic Disease "Presentation" - Amar Kishan
April 14, 2025
Details
Radiation Safety and Ecology: Comparison of Practices in the US and the World "Presentation" - Catherine Meyer
April 14, 2025
Details
Post-VISION Real World Experience in the US: How is PSMA RLT Being Used? "Presentation" - Matthew Rettig
April 14, 2025
Details
Lessons from Germany in Early Access PSMA Therapy in Clinical Practice "Presentation" - Wolfgang Fendler
April 14, 2025
Details
Pre-chemo 177Lu-PSMA Trials: PSMAfore, SPLASH, and ECLIPSE "Presentation" - Emmanuel Antonarakis
April 12, 2025
Details
How to Crush a PSMA PET Report: Guidelines and Scoring Systems "Presentation" - Phillip Kuo
April 11, 2025
Details
Can We Kill the Bone Scan? "Presentation" - Daniel Spratt
April 11, 2025
Details
PRIMARY Score and Where it Plays a Role in Prostate Cancer Diagnosis "Presentation" - Michael Hofman
April 11, 2025
Details
The Changing Role of MRI in Staging Patients with Prostate Cancer "Presentation" - Steven Raman
April 11, 2025
Details
Incorporating PSMA PET into Clinical Trials "Presentation" - Michael Morris
April 10, 2025
Details
Can PSMA-Targeted Prostate Biopsy Detect Cancer When MRI-Guided Biopsy is Negative? "Presentation" - Wayne Brisbane
April 9, 2025
Details
Role of PSMA PET in Surgical Planning and Post-Operative Management "Presentation" - Carissa Chu
April 9, 2025
Details
Whole Body PSMA Quantitative Parameters: Why Are We Not Using Whole Body PSMA PET Parameters in the Real World? "Presentation" Irène Buvat
April 9, 2025
Details
PSMA-PET for Overall Survival Outcomes Risk Stratification of Prostate Cancer "Presentation" - Wolfgang Fendler
April 9, 2025
Details
Who Benefits from Oligometastasis Directed Therapy? "Presentation" - Julian Hong
April 9, 2025
Details
Impact of Clinical Guidelines on PSMA-PET Implementation "Presentation" - Emmanuel Antonarakis
April 8, 2025
Details
Pictoral Atlas of PSMA PET "Presentation" - Matthias Benz
April 8, 2025
Details
Landscape of Approved and Upcoming PSMA Imaging Agents "Presentation" - Amir Iravani
April 8, 2025
Details
PSMA Origins "Presentation" - Martin Pomper
April 8, 2025
Details
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
